Legal Representation
Attorney
Ian W. Gillies
USPTO Deadlines
Next Deadline
1224 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20230425)
Due Date
April 25, 2029
Grace Period Ends
October 25, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 25, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 25, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 21, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Mar 18, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Feb 22, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 21, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Feb 17, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Feb 21, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Feb 17, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Feb 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 17, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 5, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 4, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Aug 22, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 1, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Aug 22, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 22, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 28, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 28, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 8, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 22, 2021 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Nov 18, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Nov 17, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 15, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 7, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 7, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 7, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 4, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 4, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 4, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 19, 2021 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Mar 28, 2021 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED | Loading... |
| Mar 24, 2021 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Feb 10, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 8, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 27, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 1, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 1, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 12, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 24, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 3, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 2, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 2, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 9, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 9, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 9, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 9, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 9, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 8, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 8, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 001
Chemicals, biochemicals, cells, and microbes for use in the manufacture of probiotic or microbe-targeted pharmaceutical preparations, for in vitro and in vivo scientific or research use, and for use in industry and science; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes for the manufacture of probiotic or microbe-targeted pharmaceutical preparations for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
First Use Anywhere:
Oct 1, 2022
First Use in Commerce:
Oct 1, 2022
Class 005
Probiotic or microbe-targeted pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids; chemical, biochemical and microbial products, namely, one or more of small molecules, proteins, antibodies, nucleic acids, probiotic bacteria, probiotic bacterial cultures, and microbes being pharmaceutical preparations and substances for the treatment, prevention, and detection of central nervous system diseases and disorders, cancer, tumors, fibrosis, inflammation, microbe-related and microbiome-related conditions, gastrointestinal and immunological diseases, and any disease or disorder associated with intestinal permeability, or leaky gut, and amyloids
First Use Anywhere:
Dec 20, 2021
First Use in Commerce:
Dec 20, 2021
Class 042
Providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; drug discovery services; pharmaceutical research; research and development of new probiotic or microbe-targeted phamaceutical products; research in the fields of biochemistry, biotechnology, and conducting clinical trials for others
First Use Anywhere:
Oct 24, 2021
First Use in Commerce:
Oct 24, 2021
Class 044
Providing medical information in the fields of diagnostic, prophylactic, and therapeutic properties of probiotic or microbe-targeted pharmaceuticals
First Use Anywhere:
Oct 24, 2021
First Use in Commerce:
Oct 24, 2021
Classification
International Classes
001
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"